Novo Nordisk announced significant new price cuts for Ozempic and Wegovy, marking one of the most aggressive pricing moves yet as the company faces mounting competition from Eli Lilly, pressure from President Donald Trump, and growing disruption from compounding pharmacies offering lower-cost alternatives.
GLP-1 drugs have become a dominant force in American health spending: 1 in 8 adults report using them for weight loss or chronic conditions.
The George Washington University has experts available for interviews on this topic. If you are interested in scheduling an interview with a GW expert please contact Katelyn Deckelbaum, katelyn [dot] deckelbaum
gwu [dot] edu (katelyn[dot]deckelbaum[at]gwu[dot]edu).
Leighton Ku, a professor of health policy and management and Director of the Center for Health Policy Research at the GW Milken Institute School of Public Health, is a health policy researcher and public policy analyst. He is an expert in national and state health reforms.
Tony Yang, is a professor in health policy at the George Washington University School of Nursing with a joint appointment at the Milken Institute School of Public Health in the Department of Health Policy and Management.
William Dietz is the director of the Sumner M. Redstone Global Center for Prevention and Wellness at the GW Milken Institute School of Public Health. He can talk in detail about the drug and the success rate with weight loss.
-GW-